Trademark: 88056127
Word
V
Status Date
Monday, October 10, 2022
Filing Date
Friday, July 27, 2018
Published for Opposition
Tuesday, July 9, 2019
Abandoned Date
Monday, October 10, 2022
5 Pharmaceuticals for use in the treatment of viral infection, bacterial infection, asthma, allergies, cancer, transplant rejection, inflammatory diseases and disorders, immune diseases and disorders, hereditary diseases and disorders, namely, metabolic, endocrine, neurologic and cardiovascular diseases or disorders, and auto immune diseases and disorders; pharmaceuticals for use in the treatment of T-cell and B-cell leukemias and lymphomas; medical therapeutic preparations, namely, biologically active modulators, biologically active immune modulators, biologically active antisense DNA or RNA compounds, chemical modulators of gene expression working at DNA transcription, RNA or translation processes; immunomodulatory oligonucleotides, namely, ingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; medical therapeutic preparations, namely, small molecule chemicals aimed at inhibiting cellular proteins
42 Medical research; scientific research; biological research; chemical research; pharmaceutical research services; pharmaceutical research and development; product research and development; medical and scientific research in the area of oligonucleotides or chemical products; medical and scientific research in the area of the structure-based drug design; biological and chemical research in the field of immunology, virology, oncology and hereditary diseases; medical and scientific research in the area of small molecule chemicals aimed at inhibiting cellular proteins for use as therapeutic agents; pharmaceutical research and development in the field of infectious diseases and disorders, cancer, viral diseases and disorders, inflammatory diseases and disorders, immunological diseases and disorders, autoimmune diseases and disorders, hereditary diseases and disorders, and cardiovascular diseases and disorders
The mark consists of an open-ended, inverted triangle with the interior space of the triangle containing shaded circles.
Color is not claimed as a feature of the mark.
Oct 11, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Oct 10, 2022
Abandonment - No Use Statement Filed
Feb 24, 2022
Notice Of Approval Of Extension Request E-Mailed
Feb 23, 2022
Sou Extension 5 Granted
Feb 16, 2022
Sou Extension 5 Filed
Feb 23, 2022
Case Assigned To Intent To Use Paralegal
Feb 16, 2022
Teas Extension Received
Sep 1, 2021
Notice Of Approval Of Extension Request E-Mailed
Aug 30, 2021
Sou Extension 4 Granted
Aug 30, 2021
Sou Extension 4 Filed
Aug 30, 2021
Teas Extension Received
Mar 5, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 3, 2021
Sou Extension 3 Granted
Mar 3, 2021
Sou Extension 3 Filed
Mar 3, 2021
Teas Extension Received
Feb 10, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 10, 2021
Teas Change Of Correspondence Received
Feb 10, 2021
Teas Withdrawal Of Attorney Received-Firm Retains
Feb 10, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 10, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Feb 10, 2021
Teas Change Of Owner Address Received
Sep 5, 2020
Notice Of Approval Of Extension Request E-Mailed
Sep 3, 2020
Sou Extension 2 Granted
Sep 3, 2020
Sou Extension 2 Filed
Sep 3, 2020
Teas Extension Received
Mar 5, 2020
Notice Of Approval Of Extension Request E-Mailed
Mar 3, 2020
Sou Extension 1 Granted
Mar 3, 2020
Sou Extension 1 Filed
Mar 3, 2020
Teas Extension Received
Sep 3, 2019
Noa E-Mailed - Sou Required From Applicant
Jul 9, 2019
Official Gazette Publication Confirmation E-Mailed
Jul 9, 2019
Published For Opposition
Jun 19, 2019
Notification Of Notice Of Publication E-Mailed
Jun 4, 2019
Assigned To Lie
May 22, 2019
Approved For Pub - Principal Register
May 14, 2019
Teas/Email Correspondence Entered
May 14, 2019
Correspondence Received In Law Office
May 14, 2019
Teas Response To Office Action Received
Nov 20, 2018
Notification Of Non-Final Action E-Mailed
Nov 20, 2018
Non-Final Action E-Mailed
Nov 20, 2018
Non-Final Action Written
Nov 14, 2018
Assigned To Examiner
Aug 3, 2018
Notice Of Design Search Code E-Mailed
Aug 2, 2018
New Application Office Supplied Data Entered In Tram
Jul 31, 2018
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
